Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor Therapeutics – totalling over €264 million.
Jeito’s current portfolio offering is valued at €534 million, with a focus on a patient-focused approach and on financing the development and growth of “ground-breaking” medical innovation.
Jeito recently participated in the upsized €199.6 million Series C financing round for Aviceda Therapeutics, the financing round was co-led by Omega Funds and TCGX, with participation from Enavate Sciences, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., and Digitalis Ventures.
The Massachusetts-based biotech company is advancing the use of advanced immunomodulators, including its lead candidate AVD-104 for geographic atrophy secondary to age-related macular degeneration. Jeito stood out as the sole European fund among the syndicate of institutional investors.
The investment will bolster Aviceda’s late-stage clinical trials for AVD-104, a next-generation therapy demonstrating dual mechanisms of action that target immune modulation and complement inhibition. Already, AVD-104 has shown promise in reducing lesion growth and enhancing visual function in earlier trials.
This financing will also aid Aviceda’s expansion into other ophthalmic indications, as it anticipates pivotal 12-month endpoint data in late 2025.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: “Our investment in Aviceda Therapeutics perfectly illustrates our ambition to champion promising late-clinical stage biopharma with the potential to become global market leaders that will make a meaningful difference in patient lives. We have been impressed by Aviceda’s new mechanism whose first positive results represent a new hope for patients. We look forward to starting this new collaboration and bringing our European expertise and global approach to accelerate this transformative therapy for patients with high unmet needs.”
Further emphasising its expertise in biopharma, Jeito led a €64.9 million Series B financing round for Pennsylvania-based XyloCor Therapeutics, a clinical-stage company at the forefront of gene therapy for cardiovascular disease.
Existing institutional investors, including EQT, Fountain Healthcare Partners, and Lumira Ventures, also participated in the round. Rachel Mears, Partner at Jeito Capital, will also join XyloCor Board of Directors.
This funding will support two Phase 2 trials for its lead asset, XC001, aimed at treating refractory angina and as an adjunctive therapy in coronary artery bypass graft surgery. The approach, leveraging endocardial administration and targeted angiogenesis, holds the potential to address the unmet needs of cardiovascular patients with limited treatment options.
Rachel Mears added: “We are thrilled to support XyloCor as it advances its clinical trials to evaluate XC001 as a potential treatment for patients struggling with the burden of cardiovascular disease. The company has strong support from an experienced leadership team, world-class cardiologists and scientists and has made impressive achievements in a short time in advancing its novel gene therapy approach. We look forward to collaborating with the company as it progresses to the next steps in its clinical programme.”
These investments highlight Jeito’s strategic focus on high-impact therapeutic areas, including ophthalmology and cardiology, as well as following the recent acquisition of portfolio company EyeBio by Merck & Co for up to €2.8 billion.
Jeito’s dual presence in Europe and the United States may position it to bridge these healthcare markets, leveraging its expertise to foster cross-continental collaborations.
Read the orginal article: https://www.eu-startups.com/2025/01/french-pe-fund-jeito-capital-invests-in-global-biopharma-growth-with-aviceda-and-xylocor-therapeutics/
